Zoledronate in the prevention of Paget's (ZiPP): protocol for a randomised trial of genetic testing and targeted zoledronic acid therapy to prevent SQSTM1-mediated Paget's disease of bone
Owen Cronin, Laura Forsyth, Kirsteen Goodman, Steff C. Lewis, Catriona Keerie, Allan Walker, Mary Porteous, Roseanne Cetnarskyj, Lakshminarayan R. Ranganath, Peter L. Selby, Geeta Hampson, Rama Chandra, Shu Ho, Jon H. Tobias, Steven Young-Min, Malachi J. McKenna, Rachel K. Crowley, William D. Fraser, Luigi Gennari, Ranuccio NutiMaria Luisa Brandi, Javier Del Pino-Montes, Jean-Pierre Devogelaer, Anne Durnez, Giancarlo Isaia, Marco Di Stefano, Núria Guañabens, Josep Blanch, Markus J. Seibel, John P. Walsh, Mark A. Kotowicz, Geoffrey C. Nicholson, Emma L. Duncan, Gabor Major, Anne Horne, Nigel L. Gilchrist, Maarten Boers, Gordon D. Murray, Keith Charnock, Diana Wilkinson, R. Graham G Russell, Stuart H. Ralston (Lead / Corresponding author)
Research output: Contribution to journal › Article › peer-review
Dive into the research topics of 'Zoledronate in the prevention of Paget's (ZiPP): protocol for a randomised trial of genetic testing and targeted zoledronic acid therapy to prevent SQSTM1-mediated Paget's disease of bone'. Together they form a unique fingerprint.